Patents by Inventor Callum M. Sloss

Callum M. Sloss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic combinations comprising anti-CD123 immunoconjugates
    Patent number: 11701428
    Abstract: Therapeutic combinations of immunoconjugates that bind to CD123 (e.g., IMGN632) with BCL-2 inhibitors (e.g., venetoclax), and/or a hypomethylating agent (e.g., azacitidine or decitabine) are provided. Methods of administering the combinations to treat hematological malignancies with clinical efficacy and/or decreased toxicity are also provided. Methods of treating hematological malignances present as minimal residual disease using immunoconjugates that bind to CD123 (e.g., IMGN632) are also provided.
    Type: Grant
    Filed: April 29, 2020
    Date of Patent: July 18, 2023
    Assignee: ImmunoGen, Inc.
    Inventors: Sharlene Adams, Callum M. Sloss, Patrick Zweidler-McKay
  • THERAPEUTIC COMBINATIONS COMPRISING ANTI-CD123 IMMUNOCONJUGATES
    Publication number: 20210023237
    Abstract: Therapeutic combinations of immunoconjugates that bind to CD123 (e.g., IMGN632) with BCL-2 inhibitors (e.g., venetoclax), and/or a hypomethylating agent (e.g., azacitidine or decitabine) are provided. Methods of administering the combinations to treat hematological malignancies with clinical efficacy and/or decreased toxicity are also provided. Methods of treating hematological malignances present as minimal residual disease using immunoconjugates that bind to CD123 (e.g., IMGN632) are also provided.
    Type: Application
    Filed: April 29, 2020
    Publication date: January 28, 2021
    Inventors: Sharlene ADAMS, Callum M. SLOSS, Patrick ZWEIDLER-MCKAY
  • COMBINATION TREATMENT WITH ANTIBODY-DRUG CONJUGATES AND CYTARABINE
    Publication number: 20190160089
    Abstract: The present invention provides a method of treating a cancer in a subject comprising administering to the subject an effective amount of a CD33-targeted antibody-drug conjugate (ADC) and an effective amount of cytarabine. Also provided are pharmaceutical compositions comprising an effective amount of a CD33-targeted ADC and an effective amount of cytarabine.
    Type: Application
    Filed: October 30, 2018
    Publication date: May 30, 2019
    Inventors: Sharlene Adams, Callum M. Sloss, Patrick Zweidler-McKay